Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:21 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 5,139 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Efavirenz; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Methamphetamine Use Disorders, HIV
Interventions: intermittent theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS), Sham TMS; Device
Lead sponsor: Gopalkumar Rakesh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HIV Infections
Interventions: Community Mobilization; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 4,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Cancer, Hiv, Stress
Interventions: SmartManage for HIV+ cancer survivors, Educational Control; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: YASMIN, GSK2248761, Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Alcohol Consumption, HIV, Motivation
Interventions: Motivational Interviewing, Questionnaire assessment, Neurocognitive assessments, Blood specimens; Behavioral · Other
Lead sponsor: University of Florida; Other
Eligibility: 25 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Hiv
Interventions: HIV D+/R+; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Nonadherence
Interventions: Pos4Health, Patient Education; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Sexually Transmitted Infection, HIV
Interventions: Tailored Socio-Contextual Intervention, Standard of Care; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 4,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more

Conditions: HIV Infection
Interventions: GW873140; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 34
States / cities: Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 15 Years and older
Enrollment: 6,100 participants
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Dependence, Drug Dependence
Interventions: Adapted Enhanced-RESPECT (HIV prevention intervention); Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2, HIV Infections, PreDiabetes
Interventions: MTM + ILI, Standard MTM; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: CAB LA, CAB ULA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Mobile, Alabama • Coral Gables, Florida • Oak Brook, Illinois

Conditions: HIV Prevention
Interventions: Tenofovir 1% gel, Vaginal product; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: San Francisco, California • The Bronx, New York

Conditions: HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions: Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: HIV Infections
Interventions: mLab App, HIV Prevention Information, HIV Home Tests; Device · Behavioral
Lead sponsor: Rebecca Schnall, RN, MPH, PhD; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Tuberculosis, AIDS-related Complex
Interventions: Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Substance Use Disorder (SUD)
Interventions: Substance use disorder screening, Social network intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Questionnaire; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV/AIDS
Interventions: Individual Telephone Counseling Intervention, Group Arm, Book Arm; Behavioral · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: HIV Infections
Interventions: Lymphocytes, Activated; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH

C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions

SmartManage Stress Management for HIV+ Cancer Survivors

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

ARCH II Study (Alcohol Research Center on HIV Study II)

HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients

Pilot RCT of Pos4Health for Nonadherent HIV+ Substance Users

Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy

Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)

Food as Medicine for HIV and Diabetes

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine

Improving Health Outcomes in Young Cisgender Men and Transgender Women (mLab App)

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

Combining Social Network Strategies and Routine Substance Use Screening

An Observational Study of People Who Have Recently Been Infected With HIV

Self-Managing HIV and Chronic Disease

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients